Pierre-Simon Rohrlich

Pierre-Simon Rohrlich

Auto-generated profile, based on publicly available information

Pierre-Simon Rohrlich

Service D’hématologie Clinique 6 , Centre Hospitalier Universitaire de Nice, Nice

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 May 2013 in Nature Communications
Verified
Journal Article
Open access
PDF file
JAJuliette Marie Albuisson
Juliette Marie Albuisson
SMSwetha E Murthy
Swetha E Murthy
MBMichael Bandell
Michael Bandell
BCBertrand Coste
Bertrand Coste
HLHélène Louis-Dit-Picard
Hélène Louis-Dit-Picard
APArdem Patapoutian
Ardem Patapoutian
Dehydrated hereditary stomatocytosis is a genetic condition with defective red blood cell membrane properties that causes an imbalance in intracellular cation concentrations. Recently, two missense mutations in the mechanically activated PIEZO1 (FAM38A) ion channel were associated with dehydrated hereditary stomatocytosis. However, it is not known how these mutations affect PIEZO1 function. Here, by combining linkage analysis and whole-exome sequencing in a large pedigree and Sanger sequencing in two additional kindreds and 11 unrelated dehydrated hereditary stomatocytosis cases, we identify three novel missense mutations and one recurrent duplication in PIEZO1, demonstrating that it is the major gene for dehydrated hereditary stomatocytosis. All the dehydrated hereditary stomatocytosis-associated mutations locate at C-terminal half of PIEZO1. Remarkably, we find that all PIEZO1 mutations give rise to mechanically activated currents that inactivate more slowly than wild-type currents. This gain-of-function PIEZO1 phenotype provides insight that helps to explain the increased permeability of cations in red blood cells of dehydrated hereditary stomatocytosis patients. Our findings also suggest a new role for mechanotransduction in red blood cell biology and pathophysiology.

3 February 2011 in Blood
Verified
Journal Article
Open access
PDF file
JSJana Pachlopnik Schmid
Jana Pachlopnik Schmid
DCDanielle Canioni
Danielle Canioni
DMDespina Moshous
Despina Moshous
FTFabien Touzot
Fabien Touzot
NMNizar Mahlaoui
Nizar Mahlaoui
SLSylvain Latour
Sylvain Latour
X-linked lymphoproliferative syndromes (XLP) are primary immunodeficiencies characterized by a particular vulnerability toward Epstein-Barr virus infection, frequently resulting in hemophagocytic lymphohistiocytosis (HLH). XLP type 1 (XLP-1) is caused by mutations in the gene SH2D1A (also named SAP), whereas mutations in the gene XIAP underlie XLP type 2 (XLP-2). Here, a comparison of the clinical phenotypes associated with XLP-1 and XLP-2 was performed in cohorts of 33 and 30 patients, respectively. HLH (XLP-1, 55%; XLP-2, 76%) and hypogammaglobulinemia (XLP-1, 67%; XLP-2, 33%) occurred in both groups. Epstein-Barr virus infection in XLP-1 and XLP-2 was the common trigger of HLH (XLP-1, 92%; XLP-2, 83%). Survival rates and mean ages at the first HLH episode did not differ for both groups, but HLH was more severe with lethal outcome in XLP-1 (XLP-1, 61%; XLP-2, 23%). Although only XLP-1 patients developed lymphomas (30%), XLP-2 patients (17%) had chronic hemorrhagic colitis as documented by histopathology. Recurrent splenomegaly often associated with cytopenia and fever was preferentially observed in XLP-2 (XLP-1, 7%; XLP-2, 87%) and probably represents minimal forms of HLH as documented by histopathology. This first phenotypic comparison of XLP subtypes should help to improve the diagnosis and the care of patients with XLP conditions.

23 April 2021 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
PBPaul Bastard
Paul Bastard
EOElizaveta Orlova
Elizaveta Orlova
LSLeila Sozaeva
Leila Sozaeva
RLRomain Lévy
Romain Lévy
AJAlyssa James
Alyssa James
Michail LionakisMichail Lionakis
Michail Lionakis
Patients with biallelic loss-of-function variants of AIRE suffer from autoimmune polyendocrine syndrome type-1 (APS-1) and produce a broad range of autoantibodies (auto-Abs), including circulating auto-Abs neutralizing most type I interferons (IFNs). These auto-Abs were recently reported to account for at least 10% of cases of life-threatening COVID-19 pneumonia in the general population. We report 22 APS-1 patients from 21 kindreds in seven countries, aged between 8 and 48 yr and infected with SARS-CoV-2 since February 2020. The 21 patients tested had auto-Abs neutralizing IFN-α subtypes and/or IFN-ω; one had anti–IFN-β and another anti–IFN-ε, but none had anti–IFN-κ. Strikingly, 19 patients (86%) were hospitalized for COVID-19 pneumonia, including 15 (68%) admitted to an intensive care unit, 11 (50%) who required mechanical ventilation, and four (18%) who died. Ambulatory disease in three patients (14%) was possibly accounted for by prior or early specific interventions. Preexisting auto-Abs neutralizing type I IFNs in APS-1 patients confer a very high risk of life-threatening COVID-19 pneumonia at any age.

12 January 2011 in Haematologica
Verified
Journal Article
Closed access
PDF file
NAN. Aladjidi
N. Aladjidi
GLG. Leverger
G. Leverger
TLT. Leblanc
T. Leblanc
MPM. Q. Picat
M. Q. Picat
GMG. Michel
G. Michel
F(For The Centre de Reference National Des Cytopenies Auto-Immunes de L'ENfant (Cerevance)
For The Centre de Reference National Des Cytopenies Auto-Immunes de L'ENfant (Cerevance)
Background Autoimmune hemolytic anemia is a rare condition in children. Little is known about its initial presentation and the subsequent progression of the disease. Design and Methods Since 2004, a national observational study has been aiming to thoroughly describe cases and identify prognostic factors. Patients from all French hematologic pediatric units have been included if they had a hemoglobin concentration less than 11 g/dL, a positive direct antiglobulin test and hemolysis. Evans’ syndrome was defined by the association of autoimmune hemolytic anemia and immunological thrombocytopenic purpura. Data from patients’ medical records were registered from birth to last follow-up. Autoimmune hemolytic anemia was classified as primary or secondary. Remission criteria, qualifying the status of anemia at last follow-up, were used with the aim of identifying a subgroup with a favorable prognosis in continuous complete remission. Results The first 265 patients had a median age of 3.8 years at diagnosis. In 74% of cases the direct antiglobulin test was IgG/IgG+C3d. Consanguinity was reported in 8% of cases and first degree familial immunological diseases in 15% of cases. Evans’ syndrome was diagnosed in 37% of cases. Autoimmune hemolytic anemia was post-infectious in 10%, immunological in 53% and primary in 37% of cases. After a median follow-up of 3 years, 4% of children had died, 28% were still treatment-dependent and 39% were in continuous complete remission. In multivariate analysis, IgG and IgG+C3d direct antiglobulin tests were associated with a lower rate of survival with continuous complete remission (adjusted hazard ratio, 0.43; 95% confidence interval, 0.21–0.86). Conclusions This nationwide French cohort is the largest reported study of childhood autoimmune hemolytic anemia. The rarity of this condition is confirmed. Subgroups with genetic predisposition and underlying immune disorders were identified.

31 January 2013 in Blood
Verified
Journal Article
Open access
PDF file
MPMarlène Pasquet
Marlène Pasquet
CBChristine Bellanné-Chantelot
Christine Bellanné-Chantelot
STSuzanne Tavitian
Suzanne Tavitian
NPNaïs Prade
Naïs Prade
BBBlandine Beaupain
Blandine Beaupain
EDEric Delabesse
Eric Delabesse
Key Points: Mutations of key transcription factor in myeloid malignancies.

1 May 2010 in Fertility and Sterility
Verified
Journal Article
Closed access
CRChristophe Roux
Christophe Roux
CAClotilde Amiot
Clotilde Amiot
GAGermain Agnani
Germain Agnani
YAYves Aubard
Yves Aubard
PRPierre-Simon Rohrlich
Pierre-Simon Rohrlich
PPPascal Piver
Pascal Piver